Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Heads Up on Monday, after Shaky Week
Amarantus Biosciences, Inc. (OTCMKTS:AMBS) is having a dramatic month, growing and sliding without a clear direction. On Friday, AMBS lost around 6% to stand at 6 cents, with volumes a bit above $311,000. The new week began with tentative buying. But the whole of past week was a struggle to break over the 7-cent levels, and AMBS barely managed it.
Those last days show that AMBS is heavily dependent on promotions and PR noise, in order to gain more significantly. Volumes for this stock react immediately to positive messages. But until now, the year has been mostly flat for AMBS.
The end of 2012 came with a serious promotion that lifted the ticker in the winter months, but we don’t know if the campaign would be repeated. AMBS was last promoted in the middle of June, and the latest spike happened after the announcement of financial results and a positive presentation in Finland.
Just like other pharma companies, AMBS attracts investors with a future-oriented strategy. The elusive big investor that is always on the horizon, and perhaps a revolutionary drug are levers that ensure great investor loyalty. But we can’t know if too much loyalty would push investors over the brink and into losses.
And AMBS has another strength, more than 8400 followers on Twitter, ready to spread any small piece of news and swell it to a greater degree. So social networks may be a source of newcomers and enthusiasts around the AMBS stock.
A similar directionless drama is playing for OncoSec Medical, Inc. (OTCMKTS:ONCS), another biotech that strives to offer unique drugs for significant ailments. But the past week has been mostly the story of a fall, as ONCS slid down around 10 cents to hover at the 26-cent levels.
At a greater price, Nano Viricides, Inc. (OTCMKTS:NNVCD) is for now trying for a post-split recovery. While NNVCD has high aspirations for a national exchange, NASDAQ or AMEX, this did not translate well into a stable stock price, and in fact the news of the split came with large-scale selling.
So if you are a Twitter follower, or otherwise fond of AMBS, keep in mind that big losses of 30 or 50% are as possible at $5 as they are at 5 cents, and avoid investing unaffordable sums, even though AMBS promises a breakthrough in potentially revolutionary treatments.